Moderna is one of the hottest stocks of the year because of its custom cancer treatment. Full Phase 3 data are set to be ...

Moderna Inc. MRNA shares are trading higher Monday as investors position ahead of detailed Phase 3 melanoma data for its ...

Moderna shares are surging ahead of a closely watched cancer data presentation in Madrid, but the company's razor-thin revenue base means a single readout could swing the stock sharply in either ...

Shares of Moderna ( MRNA ), an mRNA medicines developer, sank almost 8% on Friday, pulling back from a substantial run that ...

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share ...

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected ...

One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

Moderna (MRNA) stock rallies despite bearish views from analysts ahead of new late-stage trial data for Merck (MRK)-partnered ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...